Putting Asia’s HIV response back on track
From choice, a world of possibilities
11/6/08 2:36:52 PM
st_ma_media.indd
www.raisingvoices.org/sasa.php
Accessed: 17.11.2019
Unite for Children
First Edition
From choice, a world of possibilities
Want to change the world? Here's how...
"i asked: 'Why doesn't somebody do something?' Then I realized I was somebody"
Accountability for the global health sector strategies, 2016–2021
WHO/CDS/HIV/19.7
Guidelines.
The guidelines set out essential actions that humanitarian actors must take in order to effectively identify and respond to the needs and rights of persons with disabilities who are most at risk of being left behind in humanitarian settings.
The recommended actions in each chapter pl...ace persons with disabilities at the centre of humanitarian action, both as actors and as members of affected populations. They are specific to persons with disabilities and to the context of humanitarian action and build on existing and more general standards and guidelines.
These are the first humanitarian guidelines to be developed with and by persons with disabilities and their representative organizations in association with traditional humanitarian stakeholders. Based on the outcomes of a comprehensive global and regional multi-stakeholder consultation process, they are designed to promote the implementation of quality humanitarian programmes in all contexts and across all regions, and to establish and increase both the inclusion of persons with disabilities and their meaningful participation in all decisions that concern them.
more
An analysis from the perspective of the health sector in Latin America and the Caribbean
Washington, D.C., 2017
An information package for school staff
Operational Guidelines.
Guidelines for the development of educational programmes for MHM, including tips on the topics to address and methods to assess girls’ practices in a respectful way with practical tools
SADJ August 2016, Vol 71 no 7 p314 - p318
Clinical Review
The pre-clinical pipeline shows more innovation and diversity, with 252 agents being developed to treat WHO priority pathogens.
However, these products are in the very early stages of development and still need to be proven effective and safe. The optimistic scenario, the report indicates, is for... the first two to five products to become available in about 10 years.
more